Biblio Discovery — Demo Discovery Service

62 hasil untuk "Katja Weisel"

Menampilkan 1–20 · 0,35 detik · RSS

  1. Artikel Jurnal

    Sarcopenia and fat loss from serial CT predict survival in multiple myeloma patients undergoing stem cell transplantation

    Julian Kylies; Elias Brauneck; Matthias Priemel dkk.

    World Journal of Surgical Oncology, Vol. 23 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Frailty and sarcopenia are associated with adverse outcomes in multiple myeloma (MM), but their longitudinal changes and clinical relevance remain unclear. This study evaluated the longitudinal changes in body composition parameters derived from computed tomography (CT) scans…

  2. Artikel Jurnal

    Simultaneous onset of familial hemophagocytic lymphohistiocytosis and T-cell large granular lymphocytic leukemia in an adult

    Friederike Dierks; Finn-Ole Paulsen; Kai Lehmberg dkk.

    Annals of Hematology, Vol. 105 No. 8 · 2026 · Inggris · DOAJ Scopus

    Abstract Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome. The familial form (fHL), associated with specific genetic alterations, typically manifests in childhood, while secondary forms arise due to triggers such as malignancies or infections. We present the rare case…

  3. Artikel Jurnal

    Predicting survival of patients with spinal involvement in multiple myeloma using PATHFx 3.0 – a validation study of 100 patients in Germany

    Julian Kylies; Elias Brauneck; Tobias M. Ballhause dkk.

    World Journal of Surgical Oncology, Vol. 24 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Background Spinal malignant lesions are a common feature in multiple myeloma (MM) and often require surgical intervention. Accurate survival prediction is critical for guiding treatment decisions in these patients. While PATHFx is a widely used, machine-learning-based prognostic tool for…

  4. Artikel Jurnal

    Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

    Magdalena Benda; Patrick Reimann; Wolfgang Willenbacher dkk.

    Annals of Hematology, Vol. 105 No. 9 · 2026 · Inggris · DOAJ Scopus

    Abstract T-cell–redirecting therapies have transformed the treatment of relapsed/refractory multiple myeloma (RRMM) but are associated with substantial infection risk. We systematically reviewed infections after CAR T-cell therapy and bispecific antibodies (BsAbs), focusing on incidence, timing…

  5. Artikel Jurnal

    CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells

    Luca Julius Pape; Anna Josephine Gebhardt; Marten Dannenberg dkk.

    Scientific Reports, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, enabling endogenous antibodies to opsonize tumor cells and induce FC-dependent effector…

  6. Artikel Jurnal

    Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma

    Franziska Brauneck; Pauline Weimer; Julian Schulze zur Wiesch dkk.

    Frontiers in Medicine, Vol. 8 · 2021 · Inggris · DOAJ Scopus

    Background: γδ T cells represent a unique T cell subpopulation due to their ability to recognize cancer cells in a T cell receptor- (TCR) dependent manner, but also in a non-major histocompatibility complex- (MHC) restricted way via natural killer receptors (NKRs). Endowed with these features, they…

  7. Artikel Jurnal

    Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit

    Panagiotis Karagiannis; Felix Klingler; Viktor Arelin dkk.

    Frontiers in Oncology, Vol. 14 · 2025 · Inggris · DOAJ Scopus

    ObjectiveAnalyze the outcomes of critically ill patients who developed new-onset organ dysfunction and received systemic chemotherapy during their ICU stay.DesignRetrospective cohort study.SettingA tertiary medical center in Germany with an Intensive Care Medicine department consists of 11…

  8. Artikel Jurnal

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    Pralay Mukhopadhyay; Hesham A. Abdullah; Joanna B. Opalinska dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Patients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have…

  9. Artikel Jurnal

    Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

    Julia Hambach; William Fumey; Tobias Stähler dkk.

    Frontiers in Immunology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    CD38 is a target for immunotherapy of multiple myeloma. Llama-derived CD38-specific nanobodies allow easy reformatting into mono-, bi- and multispecific proteins. To evaluate the utility of nanobodies for constructing CD38-specific nanobody-based killer cell engagers (nano-BiKEs), we generated…

  10. Artikel Jurnal

    Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

    Katja Weisel; Meletios A. Dimopoulos; Jesús San-Miguel dkk.

    HemaSphere, Vol. 7 No. 3 · 2023 · Inggris · DOAJ Scopus

    Triplet regimens containing immunomodulatory drugs and proteasome inhibitors (PIs) have improved outcomes and extended survival for patients with relapsed/refractory multiple myeloma (RRMM). We evaluated updated health-related quality of life (HRQoL) findings from the phase 2 ELOQUENT-3 clinical…

  11. Artikel Jurnal

    Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making

    Sebastian Gonzalez-McQuire; Meletios-Athanassios Dimopoulos; Katja Weisel dkk.

    MDM Policy & Practice, Vol. 4 · 2019 · Inggris · DOAJ Scopus

    Background. We aimed to develop and validate a conceptual model of multiple myeloma (MM) that characterizes the attributes affecting disease progression and patient outcomes, and the relationships between them. Methods. Systematic and targeted literature reviews identified disease- and…

  12. Artikel Jurnal

    Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches

    Maximilian Al-Bazaz; Sven Pischke; Winfried Alsdorf dkk.

    Haematologica, Vol. 999 No. 1 · 2025 · Inggris · DOAJ Scopus

    Hepatitis E virus (HEV) is an under-recognized cause of viral hepatitis, with rising incidence in high-income countries largely driven by zoonotic transmission. Patients with multiple myeloma (MM) are especially vulnerable to HEV, yet recommendations for antiviral treatment and impact on the…

  13. Artikel Jurnal

    Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

    Steffen Krohn; Ammelie Svea Boje; Carina Lynn Gehlert dkk.

    Frontiers in Immunology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    To identify new antibodies for the treatment of plasma cell disorders including multiple myeloma (MM), a single-chain Fragment variable (scFv) antibody library was generated by immunizing mice with patient-derived malignant plasma cells. To enrich antibodies binding myeloma antigens, phage display…